A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.

Yohei ChibaKazuki SudoYuki KojimaHitomi OkumaShinji KohsakaRyunosuke MachidaMasahiko IchimuraKenta AnjoKazumi KurishitaNatsuko OkitaKenichi NakamuraIchiro KinoshitaMasanobu TakahashiJunichi MatsubaraHitoshi KusabaKan YonemoriMasamichi Takahashi

Published in: BMC cancer (2022)

Japan Registry of Clinical Trial: jRCT2031210043 (registered April 20, 2021) ClinicalTrials.gov: NCT04962867 (registered July 15, 2021).

Keyphrases

clinical trial
phase ii
phase iii
double blind
study protocol
open label
copy number
genome wide
cross sectional
randomized controlled trial
placebo controlled
genome wide identification
dna methylation
binding protein